NCT03818581View on ClinicalTrials.gov

Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL

Enrollment

108

Participants

Timeline

Start Date

March 15, 2019

Primary Completion Date

November 3, 2021

Study Completion Date

November 3, 2021

Conditions

Type 2 Diabetes MellitusInsomniaSleep DisorderInflammation

Interventions

DRUG

Suvorexant

10-mg or 20-mg Suvorexant capsules

OTHER

Placebo

Matching placebo capsules

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors

lead

Massachusetts General Hospital

OTHER

NCT03818581 - Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes | Biotech Hunter | Biotech Hunter